Lilly Flourishes in Q4 as Peer Projections Signal Looming 2025 Sector Slowdown

Eli Lilly capped 2025 with 45% revenue growth to $65.2B, driven by Mounjaro and Zepbound. But sector-wide data shows cooling optimism, with only 72% of pharma leaders reporting growth a 24-point drop from 2024.

Eli Lilly delivered blockbuster fourth-quarter results to close 2025, but fresh industry data suggests the broader pharmaceutical sector is bracing for a pronounced slowdown in 2026. Lilly reported full-year revenue of $65.2 billion, a staggering 45% increase, with its incretin portfolio Mounjaro and Zepbound generating over $13 billion in quarterly revenue. Zepbound now captures nearly 70% of new branded obesity prescriptions, while Mounjaro commands more than 55% of new U.S. diabetes prescriptions.

Yet beneath these record figures, Lilly acknowledged mounting headwinds. The company expects price to be a "low-to-mid-teens drag" on 2025 revenue growth, citing government access deals, pricing changes, and reduced Medicaid coverage. R&D spending climbed 26%, while marketing expenses rose 29%, pressuring near-term margins.

The caution extends beyond Lilly. Forvis Mazars' 2026 C-suite Barometer shows only 72% of pharma leaders now report revenue growth a sharp 24-point decline from 2025. Optimism has cooled correspondingly, with a 14-point drop in executives maintaining a positive growth outlook. Economic uncertainty and supply chain disruptions top the list of growth barriers.

ING analysts suggest 2026 will be when Trump administration policies begin to bite, with most-favored-nation proposals, tariffs, and fragmented European assessments creating a "messy, uneven" environment. For the industry at large, 2026 appears defined by consolidation rather than expansion, with talent strategy and operational optimization dominating C-suite agendas.

Wolfe Research remains bullish on Lilly specifically, raising its price target to $1,325 on expectations that oral obesity therapy orforglipron could generate $44 billion in peak revenue. But that optimism is increasingly company-specific. Whether the broader sector can navigate pricing pressures and global uncertainties without a prolonged downturn remains the central question.